Flora Lum - research works

930,411 beneficiaries underwent 12,942,057 intravitreal injections.

In the FFS group, aflibercept 2mg was used most frequently (43.8%; n = 4,271,050), followed by bevacizumab (34.7%; n = 3,382,439), ranibizumab (20.6%; n = 2,008,791), brolucizumab (0.6%; n = 56,728) and faricimab (0.4%; n = 40,729).

In the MA group, bevacizumab was used most frequently (45.1%; n = 1,436,151), followed by aflibercept 2mg (37.8%; n = 1,201,311), ranibizumab (6.5%; n = 524,758), brolucizumab (0.4%; n = 13,406), and faricimab (0.2%; n = 6,694).

47.0%; difference (diff) = 13.0%, 95% CI:12.8, 13.3%; P<.001).

The annual incidence from 2014 to 2021 in the IRIS Registry was 3.4 per 100 00 patient-years.

The average age was 67 years, with 88% of patients older than 50 years and 62% older than 65 years.

Demographics of the affected cohort were 63.8% male, 65% White, and 10% Hispanic.

Forty percent of patients with OSSN had a history of smoking, and 39% of patients were in southern US states based on US Census classification.

Of the 21 242 patients analyzed, 1703 patients underwent surgery within 6 months of amblyopia diagnosis and 19 539 did not.

In the propensity score matching cohort, among patients with baseline VA worse than 20/30, VA significantly improved over time in both the strabismus surgery and no strabismus surgery groups.

Improvement was most pronounced in the youngest group (3-7 years of age), whereas teenage patients (13-17 years of age) showed no improvement.

In multivariable logistic regression, no difference was found in the odds of treatment success, as measured by the IRIS-50, at the final follow-up between patients who underwent strabismus surgery and those who did not.